Carlos Cordon-Cardo Department of Pathology, Icahn School of Medicine at Mount Sinai, USA
1 protocol

Veronica Rodriguez-Bravo Department of Pathology, Icahn School of Medicine at Mount Sinai, USA
1 protocol

Irene Rodriguez-Fernandez Department of Pathology, Icahn School of Medicine at Mount Sinai, USA
1 protocol

Marc Carceles-Cordon Department of Pathology, Icahn School of Medicine at Mount Sinai, USA
1 protocol

Josep Domingo-Domenech
  • Department of Pathology, Icahn School of Medicine at Mount Sinai, USA
Research focus
  • Cancer biology
  • 1 Author merit


Ph.D. in Pathology & Cell Biology, School of Medicine, University of Barcelona, Spain, 2012

Current position

Assistant Professor, Mount Sinai School of Medicine, Pathology Department, New York, USA, 2012


  1. Carceles-Cordon, M., Rodriguez-Fernandez, I., Rodriguez-Bravo, V., Cordon-Cardo, C. and Domingo-Domenech, J. (2016). In vivo bioluminescence imaging of luciferase-labeled cancer cells. Bio-protocol 6(6): e1762.
  2. Tovar, V., Cornella, H., Moeini, A., Vidal, S., Hoshida, Y., Sia, D., Peix, J., Cabellos, L., Alsinet, C., Torrecilla, S., Martinez-Quetglas, I., Lozano, J. J., Desbois-Mouthon, C., Solé, M., Domingo-Domenech, J., Villanueva, A. and Llovet, J. M. (2015). Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. Gut.
  3. Williams, E. S., Rodriquez-Bravo, V., Chippada-Venkata, U., De Ia Iglesia-Vicente, J., Gong, Y., Galsky, M., Oh, W., Cordon-Cardo, C. and Domingo-Domenech, J. (2015). Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells. J Vis Exp(105): 53182.
  4. Vidal, S. J., Rodriguez-Bravo, V., Quinn, S. A., Rodriguez-Barrueco, R., Lujambio, A., Williams, E., Sun, X., de la Iglesia-Vicente, J., Lee, A., Readhead, B., Chen, X., Galsky, M., Esteve, B., Petrylak, D. P., Dudley, J. T., Rabadan, R., Silva, J. M., Hoshida, Y., Lowe, S. W., Cordon-Cardo, C. and Domingo-Domenech, J. (2015). A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer. Cancer Cell 27(2): 223-239.
  5. Vidal, S. J., Quinn, S. A., de la Iglesia-Vicente, J., Bonal, D. M., Rodriguez-Bravo, V., Firpo-Betancourt, A., Cordon-Cardo, C. and Domingo-Domenech, J. (2014). Isolation of cancer stem cells from human prostate cancer samples. J Vis Exp(85).
  6. Vidal, S. J., Rodriguez-Bravo, V., Galsky, M., Cordon-Cardo, C. and Domingo-Domenech, J. (2014). Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene 33(36): 4451-4463.
  7. Galsky, M. D. and Domingo-Domenech, J. (2013). Advances in the management of muscle-invasive bladder cancer through risk prediction, risk communication, and novel treatment approaches. Clin Adv Hematol Oncol 11(2): 86-92.
  8. Jia, A. Y., Castillo-Martin, M., Domingo-Domenech, J., Bonal, D. M., Sánchez-Carbayo, M., Silva, J. M. and Cordon-Cardo, C. (2013). A common MicroRNA signature consisting of miR-133a, miR-139-3p, and miR-142-3p clusters bladder carcinoma in situ with normal umbrella cells. Am J Pathol 182(4): 1171-1179.
  9. Domingo-Domenech, J., Vidal, S. J., Rodriguez-Bravo, V., Castillo-Martin, M., Quinn, S. A., Rodriguez-Barrueco, R., Bonal, D. M., Charytonowicz, E., Gladoun, N., de la Iglesia-Vicente, J., Petrylak, D. P., Benson, M. C., Silva, J. M. and Cordon-Cardo, C. (2012). Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell 22(3): 373-388.
  10. Shen, T. H., Gladoun, N., Castillo-Martin, M., Bonal, D., Domingo-Domenech, J., Charytonowicz, D. and Cordon-Cardo, C. (2012). A BAC-based transgenic mouse specifically expresses an inducible Cre in the urothelium. PLoS One 7(4): e35243.
  11. Wosnitzer, M. S., Domingo-Domenech, J., Castillo-Martin, M., Ritch, C., Mansukhani, M., Petrylack, D. P., Benson, M. C., McKiernan, J. M. and Cordon-Cardo, C. (2011). Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy. J Urol 186(5): 2094-2100.
  12. Karni-Schmidt, O.*, Castillo-Martin, M.*, Shen, T. H., Gladoun, N., Domingo-Domenech, J., Sanchez-Carbayo, M., Li, Y., Lowe, S., Prives, C. and Cordon-Cardo, C. (2011). Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol 178(3): 1350-1360.
  13. Castillo-Martin, M., Domingo-Domenech, J., Karni-Schmidt, O., Matos, T. and Cordon-Cardo, C. (2010). Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol 28(4): 401-408.
  14. Conill, C., Valduvieco, I., Domingo-Domènech, J., Arguis, P., Vidal-Sicart, S. and Vilalta, A. (2009). Loco-regional control after postoperative radiotherapy for patients with regional nodal metastases from melanoma. Clin Transl Oncol 11(10): 688-693.
  15. Domingo-Domenech, J., Pippa, R., Tapia, M., Gascon, P., Bachs, O. and Bosch, M. (2008). Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells. Breast Cancer Res Treat 112(1): 53-62.
  16. Grau, J. J., Caballero, M., Monzo, M., Munoz-Garcia, C., Domingo-Domenech, J., Navarro, A., Conill, C., Campayo, M. and Bombi, J. A. (2008). Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy. J Surg Oncol 98(2): 130-134.
  17. Domingo-Domenech, J., Fernandez, P. L., Filella, X., Martinez-Fernandez, A., Molina, R., Fernandez, E., Alcaraz, A., Codony, J., Gascon, P. and Mellado, B. (2008). Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. Ann Oncol 19(2): 269-275.
  18. Temozolomida en pacientes con metástasis cerebrales de melanoma tratados con irradiación holocraneal. Conill Llobet, C., Valduvieco Ruiz, I., Vargas Rugeles y, M., Domingo-Doménech, J. (2008). Capítulo 5. Evidencia vs Experiencia – Temozolomida – Tumores cerebrales. Book chapter (Spanish).
  19. Caballero, M., Grau, J. J., Blanch, J. L., Domingo-Domenech, J., Auge, J. M., Jimenez, W. and Bernal-Sprekelsen, M. (2007). Serum vascular endothelial growth factor as a predictive factor in metronomic (weekly) Paclitaxel treatment for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 133(11): 1143-1148.
  20. Domingo-Domenech, J., Castel, T., Auge, J. M., Garcia-Albeniz, X. A., Conill, C., Puig, S., Vilella, R., Matas, J., Malvehy, J., Gascon, P., Mellado, B. and Molina, R. (2007). Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients. Tumour Biol 28(5): 264-272.
  21. Conill, C., Jorcano, S., Domingo-Domenech, J., Marruecos, J., Vilella, R., Malvehy, J., Puig, S., Sanchez, M., Gallego, R. and Castel, T. (2007). Toxicity of combined treatment of adjuvant irradiation and interferon alpha2b in high-risk melanoma patients. Melanoma Res 17(5): 304-309.
  22. Conill, C., Marruecos, J., Verger, E., Berenguer, J., Lomeña, F., Domingo-Domènech, J., Grau, J. J. and Casas, F. (2007). Clinical outcome in patients with intramedullary spinal cord metastases from lung cancer. Clin Transl Oncol 9(3): 172-176.
  23. Conill, C., Gimferrer, J. M., Marruecos, J., Domingo-Domènech, J., Vilella, R., Catalán, M., Malvehy, J., Puig, S. and Castel, T. (2007). Clinical outcome after surgical resection of lung metastases from melanoma. Clin Transl Oncol 9(1): 48-52.
  24. Domingo-Domenech, J., Oliva, C., Rovira, A., Codony-Servat, J., Bosch, M., Filella, X., Montagut, C., Tapia, M., Campas, C., Dang, L., Rolfe, M., Ross, J. S., Gascon, P., Albanell, J. and Mellado, B. (2006). Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res 12(18): 5578-5586.
  25. Grau, J. J., Palmero, R., Marmol, M., Domingo-Domenech, J., Monzó, M., Fuster, J., Vidal, O., Fondevila, C. and Garcia-Valdecasas, J. C. (2006). Time-related improvement of survival in resectable gastric cancer: the role of Japanese-style gastrectomy with D2 lymphadenectomy and adjuvant chemotherapy. World J Surg Oncol 4: 53.
  26. Conill, C., Jorcano, S., Domingo-Domènech, J., Gallego, R., Malvehy, J., Puig, S., Sanchez, M., Vilella, R. and Castel, T. (2006). Whole brain irradiation and temozolomide based chemotherapy in melanoma brain metastases. Clin Transl Oncol 8(4): 266-270.
  27. Codony-Servat, J., Tapia, M. A., Bosch, M., Oliva, C., Domingo-Domènech, J., Mellado, B., Rolfe, M., Ross, J. S., Gascón, P., Rovira, A. and Albanell, J. (2006). Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 5(3): 665-675.
  28. Domingo-Domènech, J., Mellado, B., Ferrer, B., Truan, D., Codony-Servat, J., Sauleda, S., Alcover, J., Campo, E., Gascon, P., Rovira, A., Ross, J. S., Fernandez, P. L. and Albanell, J. (2005). Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer 93(11): 1285-1294.
  29. Domingo-Domènech, J., Molina, R., Castel, T., Montagut, C., Puig, S., Conill, C., Martí, R., Vera, M., Auge, J. M., Malvehy, J., Grau, J. J., Gascón, P. and Mellado, B. (2005). Serum protein s-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon--comparison with tyrosinase rt-PCR. Oncology 68(4-6): 341-349.
  30. Molina, R., Auge, J. M., Filella, X., Viñolas, N., Alicarte, J., Domingo, J. M. and Ballesta, J. C. (2005). Pro-gastrinreleasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. Antican Res 25(3A):1773-1778.
  31. Grau, J. J., Domingo-Domènech, J., Morente, V., Pera, M., Garcia-Valdecasas, J. C., Fuster, J., Bombi, A., Mellado, B., Albanell, J. and Gascón, P. (2004). Low thymidylate synthase expression in the primary tumor predicts favorable clinical outcome in resected gastric cancer patients treated with adjuvant tegafur. Oncology 66(3): 226-233.
  32. Manual de trasplante hematopoyetico. Enric Carreras y Josep Domingo-Domenech. (2004). Capitulo 8. Book chapter (Spanish).
  33. Mellado, B., Del Carmen Vela, M., Colomer, D., Gutierrez, L., Castel, T., Quinto, L., Fontanillas, M., Reguart, N., Domingo-Domènech, J. M., Montagut, C., Estapé, J. and Gascón, P. (2002). Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon. J Clin Oncol 20(19): 4032-4039.
  34. Grau, J. J., Domingo, J., Blanch, J. L., Verger, E., Castro, V., Nadal, A., Alós, L. and Estapé, J. (2002). Multidisciplinary approach in advanced cancer of the oral cavity: outcome with neoadjuvant chemotherapy according to intention-to-treat local therapy. A phase II study. Oncology 63(4): 338-345.
  35. Domingo-Domènech, J., Fernandez, J., Lopez-Guillermo, A. and Miquel, R. (2002). [Fulminant hepatic failure as form of presentation of a peripheral T cell lymphoma]. Med Clin (Barc) 119(18): 715-716.
1 Protocol published
In vivo Bioluminescence Imaging of Luciferase-labeled Cancer Cells
Over the past decade, in vivo bioluminescent imaging has emerged as a non-invasive and sensitive tool for studying ongoing biological processes within living organisms (Contag et al., 1997; Contag et al., 1998). Based on ...
We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.